Literature DB >> 26064279

Association between Fas/FasL polymorphism and susceptibility to leukemia: a meta-analysis.

Yiran Chen1, Yiho He1, Xiaotong Lu1, Zhirui Zeng1, Chen Tang1, Tongyuan Xue2, Yuhua Li2.   

Abstract

The polymorphisms in Fas/FasL system were proposed to be associated with susceptibility to leukemia, but recent studies reported controversial findings. Hence, we performed a meta-analysis to assess the association between Fas gene polymorphisms and susceptibility to leukemia. We carried out a literature search in PubMed, Embase, Web of Science and CNKI databases for studies on the associations between Fas/FasL gene polymorphisms and susceptibility to leukemia. The associations were assessed by odds ratio (OR) together with its 95% confidence intervals (CIs). 7 literatures and 14 studies with a total of 8787 subjects were eventually included into our meta-analysis. Overall, there was no association between Fas/FasL polymorphisms and susceptibility to leukemia. In subgroup analysis by ethnicity, there was also no association between Fas/FasL polymorphisms and susceptibility to leukemia in Asians and Caucasians. In addition, there was also a significant association between Fas-1377G/A polymorphism and susceptibility to leukemia in ALL patients, the A allele seemed to be a protective factor in ALL risk. In summary, more studies with large sample size are needed to provide further evidence for association between Fas/FasL polymorphisms and susceptibility to leukemia.

Entities:  

Keywords:  Leukemia; meta-analysis; polymorphism

Year:  2015        PMID: 26064279      PMCID: PMC4443113     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  27 in total

1.  C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.

Authors:  Y Satoh; I Matsumura; H Tanaka; H Harada; Y Harada; K Matsui; M Shibata; M Mizuki; Y Kanakura
Journal:  Leukemia       Date:  2011-08-12       Impact factor: 11.528

2.  FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China.

Authors:  Meilin Wang; Dongmei Wu; Ming Tan; Weida Gong; Hengchuan Xue; Hongbin Shen; Zhengdong Zhang
Journal:  Biochem Genet       Date:  2009-06-30       Impact factor: 1.890

Review 3.  Association between the FAS rs2234767G/A polymorphism and cancer risk: a systematic review and meta-analysis.

Authors:  Xin Wang; Guo-Hong Xing; Chang-Chun Fan
Journal:  DNA Cell Biol       Date:  2014-02-25       Impact factor: 3.311

Review 4.  Molecular biomarkers in chronic lymphocytic leukemia.

Authors:  Sami Malek
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 5.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

6.  Association between FAS polymorphism and prostate cancer development.

Authors:  L Lima; A Morais; F Lobo; F M Calais-da-Silva; F E Calais-da-Silva; R Medeiros
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-07-31       Impact factor: 5.554

7.  High-throughput association testing on DNA pools to identify genetic variants that confer susceptibility to acute myeloid leukemia.

Authors:  Sara Rollinson; James M Allan; Graham R Law; Philippa L Roddam; Martyn T Smith; Christine Skibola; Alexandra G Smith; Matthew S Forrest; Kathryn Sibley; Russell Higuchi; Soren Germer; Gareth J Morgan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-05       Impact factor: 4.254

8.  Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia.

Authors:  Kathryn Sibley; Sara Rollinson; James M Allan; Alexandra G Smith; Graham R Law; Philippa L Roddam; Christine F Skibola; Martyn T Smith; Gareth J Morgan
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

Review 9.  Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.

Authors:  Yeqiong Xu; Bangshun He; Rui Li; Yuqin Pan; Tianyi Gao; Qiwen Deng; Huiling Sun; Guoqi Song; Shukui Wang
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

10.  Association of Fas -1377 G/A polymorphism with susceptibility to cancer.

Authors:  Peiliang Geng; Jianjun Li; Juanjuan Ou; Ganfeng Xie; Ning Wang; Lisha Xiang; Rina Sa; Chen Liu; Hongtao Li; Houjie Liang
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

View more
  3 in total

1.  Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.

Authors:  Aziati Azwari Annuar; Ravindran Ankathil; Nazihah Mohd Yunus; Azlan Husin; Nur Shafawati Ab Rajab; Ahmad Aizat Abdul Aziz; Mohd Ismail Ibrahim; Sarina Sulong
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

2.  Fas-670A>G polymorphism is not associated with an increased risk of acute myeloid leukemia development.

Authors:  Ying Huang; Donghong Deng; Hongying Li; Qiang Xiao; Lulu Huang; Bing Zhang; Fanghui Ye; Bingbing Ye; Zengnan Mo; Xiaobo Yang; Zhenfang Liu
Journal:  Biomed Rep       Date:  2015-12-31

3.  FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin.

Authors:  Shizhi Wang; Shenshen Wu; Qingtao Meng; Xiaobo Li; Jinchun Zhang; Rui Chen; Meilin Wang
Journal:  Sci Rep       Date:  2016-01-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.